Siltuximab
Interleukin Inhibitors
Sold as SYLVANT
- Drug class
- Interleukin Inhibitors
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 5
Overview
Siltuximab is an active pharmaceutical ingredient in the Interleukin Inhibitors group (L04AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | February 27, 2026 |
| CA Canada | Health Canada | 2 | November 27, 2025 |
| EU European Union | EMA | 1 | March 24, 2026 |
GBUnited Kingdom· MHRA
2 products
Uses
SYLVANT is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
How to take
CACanada· Health Canada
2 products
Uses
AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 3 WARNINGS AND PRECAUTIONS .........................................................................................
3 ADVERSE REACTIONS ........................................................................................................... 7 DRUG INTERACTIONS .........................................................................................................
15 DOSAGE AND ADMINISTRATION ..................................................................................... 15 OVERDOSAGE .......................................................................................................................
17 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 17 STORAGE AND STABILITY ................................................................................................. 19 SPECIAL HANDLING INSTRUCTIONS ..............................................................................
EUEuropean Union· EMA
1 product
Uses
SYLVANT is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
How to take
Drug interactions
Known interactions involving Siltuximab. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB441850006 · revised February 27, 2026
- [2]Health Canada (DPD) · 02435128 · revised November 27, 2025
- [3]European Medicines Agency · EMEA/H/C/003708 · revised March 24, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.